

Lonza to invest in long-term growing Meta™ metaldehyde business

Basel, Switzerland, 10 August 2011 – Lonza today announced an investment of CHF 5.8 million in a formulation plant for Meta™ metaldehyde. This will enable Lonza to supply its own formulations, allowing the company in the future to serve the market not only with metaldehyde as an active substance, but also with ready-made slug pellets.

The establishment of this formulation plant, which is expected to become operational in the second half of 2012, is part of the Nutrition business unit's consistent implementation of its strategic focus. The formulation of slug pellets will enable the company to add a further planned link in the value chain toward end-customers.

"By developing ready-made slug pellets, we are building up a distinct and independent position and will be able to create the necessary proximity to the market to drive innovations," said Roman Quinter, Head of the Nutrition business unit. "With our state-of-the-art formulation plant, we are establishing high quality and safety standards in the molluscicide business and complying with stricter regulatory and environmental requirements."

Construction of the formulation plant in Visp, Switzerland, will strengthen the site in its strategy to supply technologically demanding products with a high degree of in-house contribution in the areas of technology, processes and patentability.

About Lonza

Lonza is one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries. Products and services span its customers' needs from research to final product manufacture. It is the global leader in the production and support of active pharmaceutical ingredients both chemically as well as biotechnologically. Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. Lonza has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts which play an important role in the development of novel medicines and healthcare products. In addition, Lonza is a leader in cell-based research, endotoxin detection and cell therapy manufacturing. Furthermore, the company is a leading provider of value chemical and biotech ingredients to the nutrition, hygiene, preservation, agro and personal care markets.

Lonza is headquartered in Basel, Switzerland and is listed on the SIX Swiss Exchange. In 2010, the company had sales of CHF 2.680 billion. Further information can be found at www.lonza.com.

Corporate

Lonza

Lonza Group Ltd
Muenchensteinerstrasse 38
4002 Basel, Switzerland
www.lonza.com

Press release

For further information:

Lonza Group Ltd
Head of Corporate Communications
Dominik Werner
Tel +41 61 316 8798
Fax +41 61 316 9798
dominik.werner@lonza.com

Lonza Group Ltd
Investor Relations
Dirk Oehlers
Tel +41 61 316 8540
Fax +41 61 316 9540
dirk.oehlers@lonza.com

Lonza Group Ltd
Media Relations
Melanie Disa
Tel +1 201 316 9413
Fax +1 201 696 3533
melanie.disa@lonza.com